Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$1.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Leon Oliver Moulder Jr.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 167
- Beta
- -1.02
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.70
Financials
Revenue
$1.00M-98.0%Net Income
$-111.46MEBITDA
$-101.04MFree Cash Flow
$-57.24MEPS (diluted)
$-1.77Shares Outstanding (diluted)
63.11M+64.7%Operating Expenses
$78.66MCash & Debt
$643.13MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.00M | $-377.74M | $-8.44 |
| 2024 | $5.00M | $-156.99M | $-3.76 |
| 2023 | $50.00M | $-37.12M | $-0.97 |
| 2022 | $0.00 | $-119.28M | $-3.11 |
Valuation
ZBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+37.50%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·1d ago·Positive
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances covering operations into late 2028, though financing risk remains if FDA approval is delayed. Obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in o…
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
…enas BioPharma to Host Obexelimab IgG4-RD Investor Event WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
…a to Present at Upcoming Healthcare Investor Conferences WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management's presentations at the following investor conferences: Citi Biopharma Back to School Confe…
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…s and investments of $673.9 million as of June 30, 2026 - WALTHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-1.24 per share
Typical surprise -31.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.77 vs $-1.12miss
- Wed, May 13$-1.46 vs $-1.37miss
- Mon, Mar 16$-4.54 vs $-1.06miss
- Wed, Nov 12$-1.22 vs $-0.87miss
- Tue, Aug 12$-1.25 vs $-1.02miss
- Thu, May 15$-0.80 vs $-1.11beat
Estimates and results for ZBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZBIO officers and directors.
- Bought
- $51.7m
- Sold
- —
39 trades
0 trades
- Moulder Leon O Jrbought
- Moulder Leon O Jrbought
- Moulder Leon O Jrbought
- Lu Hongbobought
- Fairmount Funds Management Llcbought
- Moulder Leon O Jrbought
- Lu Hongbobought
- Moulder Leon O Jrbought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.